Companies /Healthcare

AbCellera Biologics Inc

NASDAQ: ABCL Biotechnology
$11.02
▼ $0.01 (−0.09%) today
Markets closed · 10:40pm ET

24/7 Wall St. View

ABCL at a Glance

Valuation
Market cap
$3.6B
Profitability
Revenue (TTM)
$67.9M
Profit margin
-218.6%
EPS (TTM)
$-0.48
Price
52-week range
$3 – $15
Street target
$18.67
Earnings
Q3 2026 EPS
$-0.13
vs. $-0.18 est.
+26.8%

Headquartered in Vancouver, BC Fiscal year ends December NASDAQ: ABCL abcellera.com

About AbCellera Biologics

AbCellera Biologics is a clinical-stage biotechnology company that discovers and develops first-in-class antibody-based medicines in endocrinology, women's health, immunology, oncology and other areas. It is moving from a partner-focused antibody discovery model, which generates research fees, licensing revenue and downstream stakes in partner programs (34 partner-led programs and 12 clinical-stage molecules as of September 30, 2026), toward developing its own drugs. Its lead asset is ABCL635, an NK3R antagonist antibody with positive Phase 2 data in menopausal vasomotor symptoms. The company plans late-stage development for that indication and expansion into VMS associated with breast and prostate cancer treatment in 2027. Its earlier pipeline includes ABCL992 (a half-life-extended ABCL635 analog), ABCL688 (autoimmunity), ABCL386 and ABCL385 (oncology), and ABCL646 (an ion channel antagonist). ABCL575, an anti-OX40L antibody, completed Phase 1 but will not be developed further. The company is funded by more than $790 million in cash and marketable securities plus over $100 million in available government funding. Updated

Revenue by Segment · Q3 2026
  1. Research Fees99%
  2. Licensing and Royalty Revenue1%

Latest Activity

ABCLAbCellera Biologics
Q3 2026
EPS
-$0.13
est -$0.18+26.8%
Revenue
$11M
est $6M+70.3%

Phase 2 data for hot flash antibody ABCL635 showed an 83% reduction in frequency versus 33% on placebo, enough to pull in an oversubscribed $200 million raise. Operating costs fell hard, narrowing the net loss to $40.8 million from $57.1 million a year ago. Twelve-week data lands in early 2027.

Quarterly EPS — reported vs estimate

ABCL Coverage

Frequently Asked Questions

What does AbCellera Biologics do?

AbCellera Biologics is a clinical-stage biotechnology company that discovers and develops first-in-class antibody-based medicines in endocrinology, women's health, immunology, oncology and other areas.

What is the ABCL stock price target?

The Wall Street consensus 12-month price target for ABCL is $18.67.